Stock Track | MBX Biosciences Soars 5.92% Intraday on Positive Obesity Drug Data and Analyst Upgrades

Stock Track

May 11

MBX Biosciences' stock surged 5.92% during intraday trading on Monday, following the release of encouraging clinical trial updates for its obesity drug pipeline and subsequent positive analyst actions.

The company announced preliminary blinded Phase 1 data for its GLP-1/GIP co-agonist prodrug, MBX 4291, demonstrating a mean weight loss of 7% at eight weeks in the first multiple ascending dose cohort. The data indicated the drug was generally well-tolerated, with a pharmacokinetic profile supporting the potential for once-monthly dosing, a key differentiator in the competitive obesity treatment market. MBX Biosciences also nominated MBX 5765, a novel GLP-1/GIP/glucagon/DACRA agonist designed for once-monthly dosing, as its next development candidate.

Analysts reacted positively to the news. Truist Securities raised its price target on MBX Biosciences to $70 from $50, maintaining a Buy rating. Separately, Guggenheim reiterated a Buy rating with an $88 price target. The company also recently reported a quarterly earnings beat, with an adjusted loss per share of $0.51, better than the consensus estimate for a loss of $0.58.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1130438263"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130438263\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130438263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130438263","market":"sg","top_or_hot":-1,"title":"Stock Track | MBX Biosciences Soars 5.92% Intraday on Positive Obesity Drug Data and Analyst Upgrades","media":"Stock Track","content":"<p>MBX Biosciences' stock surged 5.92% during intraday trading on Monday, following the release of encouraging clinical trial updates for its obesity drug pipeline and subsequent positive analyst actions.</p><p>The company announced preliminary blinded Phase 1 data for its GLP-1/GIP co-agonist prodrug, MBX 4291, demonstrating a mean weight loss of 7% at eight weeks in the first multiple ascending dose cohort. The data indicated the drug was generally well-tolerated, with a pharmacokinetic profile supporting the potential for once-monthly dosing, a key differentiator in the competitive obesity treatment market. MBX Biosciences also nominated MBX 5765, a novel GLP-1/GIP/glucagon/DACRA agonist designed for once-monthly dosing, as its next development candidate.</p><p>Analysts reacted positively to the news. Truist Securities raised its price target on MBX Biosciences to $70 from $50, maintaining a Buy rating. Separately, Guggenheim reiterated a Buy rating with an $88 price target. The company also recently reported a quarterly earnings beat, with an adjusted loss per share of $0.51, better than the consensus estimate for a loss of $0.58.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MBX Biosciences Soars 5.92% Intraday on Positive Obesity Drug Data and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MBX Biosciences Soars 5.92% Intraday on Positive Obesity Drug Data and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-11 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MBX Biosciences' stock surged 5.92% during intraday trading on Monday, following the release of encouraging clinical trial updates for its obesity drug pipeline and subsequent positive analyst actions.</p><p>The company announced preliminary blinded Phase 1 data for its GLP-1/GIP co-agonist prodrug, MBX 4291, demonstrating a mean weight loss of 7% at eight weeks in the first multiple ascending dose cohort. The data indicated the drug was generally well-tolerated, with a pharmacokinetic profile supporting the potential for once-monthly dosing, a key differentiator in the competitive obesity treatment market. MBX Biosciences also nominated MBX 5765, a novel GLP-1/GIP/glucagon/DACRA agonist designed for once-monthly dosing, as its next development candidate.</p><p>Analysts reacted positively to the news. Truist Securities raised its price target on MBX Biosciences to $70 from $50, maintaining a Buy rating. Separately, Guggenheim reiterated a Buy rating with an $88 price target. The company also recently reported a quarterly earnings beat, with an adjusted loss per share of $0.51, better than the consensus estimate for a loss of $0.58.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBX","symbol_name":"MBX Biosciences","start_time":0,"source_url":"","article_id":"1130438263","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130438263","pubTimestamp":1778510776,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MBX Biosciences' stock surged 5.92% during intraday trading on Monday, following the release of encouraging clinical trial updates for its obesity drug pipeline and subsequent positive analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBX":"MBX Biosciences"},"translate_title":"个股追踪|MBX Biosciences盘中大涨5.92%，因肥胖药物数据利好及分析师上调评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBX":1},"content_text":"MBX Biosciences' stock surged 5.92% during intraday trading on Monday, following the release of encouraging clinical trial updates for its obesity drug pipeline and subsequent positive analyst actions.The company announced preliminary blinded Phase 1 data for its GLP-1/GIP co-agonist prodrug, MBX 4291, demonstrating a mean weight loss of 7% at eight weeks in the first multiple ascending dose cohort. The data indicated the drug was generally well-tolerated, with a pharmacokinetic profile supporting the potential for once-monthly dosing, a key differentiator in the competitive obesity treatment market. MBX Biosciences also nominated MBX 5765, a novel GLP-1/GIP/glucagon/DACRA agonist designed for once-monthly dosing, as its next development candidate.Analysts reacted positively to the news. Truist Securities raised its price target on MBX Biosciences to $70 from $50, maintaining a Buy rating. Separately, Guggenheim reiterated a Buy rating with an $88 price target. The company also recently reported a quarterly earnings beat, with an adjusted loss per share of $0.51, better than the consensus estimate for a loss of $0.58.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}